Liftstream is an executive search recruitment company in the life sciences sector Novartis scores FDA breakthrough-designation for rare disease product Posted on August 30, 2013 by admin Authored by Karl Simpson Read the full article… Posted in Orphan Drugs and Rare Diseases | Tagged American Neurological Association, antibody, bimagrumab, Breakthrough Therapy, BYM338, cancer, celgene, COPD, FDA, HuCAL, mAb, MOR202, Morphosys, muscle wasting, Novartis, Orphan Drug, Rare Disease, sIBM | Leave a comment Sign up for our mailing list. Email Address : Navigate Liftstream Blog Liftstream Website Archives June 2022 November 2020 October 2020 August 2020 May 2020 April 2020 March 2020 January 2020 January 2019 October 2018 September 2018 June 2018 April 2018 March 2018 February 2018 January 2018 November 2017 March 2017 January 2017 November 2016 August 2016 July 2016 April 2016 March 2016 February 2016 January 2016 December 2015 November 2015 October 2015 September 2015 August 2015 July 2015 June 2015 May 2015 March 2015 October 2014 September 2014 August 2014 July 2014 June 2014 May 2014 April 2014 March 2014 February 2014 January 2014 December 2013 November 2013 October 2013 September 2013 August 2013 July 2013 June 2013 April 2013 March 2013 February 2013 January 2013 December 2012 November 2012 October 2012 September 2012 August 2012 January 2012 November 2011 August 2011 June 2011 May 2011 April 2011 March 2011 Search for: Recent Posts 7 Human Capital Management practices for a biotech CEO focused on people Biopharma Boards Require Lead Independent Directors Writing a Board CV Biotech Companies Acting on Promises to Increase Racial Diversity Corporate Leaders Face Pressure from Investors, Regulators to Act on Diversity Categories Board Director Appointments Corporate Governance Diversity and Inclusion Consulting Executive Appointments General Insights Job Hunting Advice M&A Finance and Funding Medical Device Orphan Drugs and Rare Diseases Pharmaceutical business Recruitment Market Uncategorized Workplace Diversity Tags#InvestinBioMgt AstraZeneca Bay Area Cluster biotech biotechnology bioValley board appointment Board of Directors Boston Biotech Boston Biotech cluster cancer celgene CEO Chairman Chief Medical Officer corporate governance Diversity EMA europe executive appointment FDA funding gender diversity Gene therapy Genzyme GSK IPO Liftstream London Biotech M&A Medicon Valley Novartis oncology Orphan drugs Oxford Biotech Prosensa Rare Disease rare diseases Roche San Diego Shire Third Rock Ventures USA venture capital women on boards
